EURURO Vol. 72 No. 6

Table 1 – Baseline characteristics for men with prostate cancer in

[11_TD$DIFF]

Sweden 3.0 who received GnRH agonists or orchiectomy as

primary treatment

GnRH agonists as primary treatment in

experimental unit

0–33%

34–66%

67–100%

Year of diagnosis

1992–1993

31 (0–100)

12 (0–0)

2 (0–0)

1994–1995

19 (0–0)

11 (0–0)

6 (0–0)

1996–1997

41 (0–100)

34 (0–100)

31 (0–100)

1998–1999

9 (0–0)

43 (0–100)

61 (0–100)

Age at diagnosis

Median

80 (75.5–83)

77 (72–82)

74 (66–77)

70 yr

5 (0–0)

11 (0–0)

30 (0–100)

70–74 yr

11 (0–0)

23 (0–100)

22 (0–100)

75–79 yr

30 (0–100)

29 (0–100)

24 (0–0)

80+ yr

54 (0–100)

37 (0–100)

24 (0–0)

T stage

T1a/b

3 (0–6)

2 (0–5)

2 (0–0)

T1c

2 (0–0)

4 (0–7)

6 (0–9)

29 (14–48)

24 (15–36)

25 (12–39)

51 (33–62)

52 (40–62)

52 (40–64)

12 (0–19)

15 (5–21)

13 (0–20)

TX/missing

2 (0–0)

2 (0–3)

2 (0–0)

N stage

2 (0–0)

3 (0–4)

2 (0–3)

2 (0–0)

3 (0–6)

6 (0–11)

NX/missing

96 (94–100)

94 (91–100) 91 (83–100)

M stage

20 (5–31)

25 (12–37)

31 (14–43)

34 (22–48)

37 (25–52)

34 (21–50)

MX/missing

46 (22–67)

38 (13–56)

35 (12–50)

Prostate–specific antigen

Median

87 (63.5–135.5) 79 (55–113) 65 (48.8–105.1)

25 ng/ml

17 (7–22)

18 (10–23)

22 (11–29)

25–

50 ng/ml

16 (7–24)

19 (12–25)

19 (10–26)

50–

100 ng/ml

18 (10–25)

17 (11–25)

19 (11–26)

100–

200 ng/ml

15 (6–19)

14 (6–19)

13 (6–20)

200–

500 ng/ml

13 (4–20)

14 (6–19)

12 (6–18)

500 ng/ml

14 (5–22)

16 (9–21)

13 (6–20)

Missing

7 (0–10)

3 (0–5)

2 (0–0)

Gleason score

2–6

18 (6–24)

18 (8–25)

18 (9–27)

44 (30–55)

40 (27–54)

41 (28–50)

8–10

35 (24–48)

39 (25–50)

39 (26–50)

Missing

4 (0–6)

3 (0–5)

3 (0–4)

Charlson comorbidity index

65 (57–75)

65 (59–77)

67 (58–79)

18 (10–24)

19 (11–24)

17 (9–22)

17 (10–22)

16 (8–21)

16 (7–22)

Previous conditions within 5 yr before diagnosis

Cardiovascular disease

Yes

33 (22–41)

31 (19–40)

28 (17–37)

67 (59–78)

69 (60–81)

72 (63–83)

Hypertension

Yes

6 (0–9)

7 (0–10)

6 (0–10)

94 (91–100)

93 (90–100) 94 (90–100)

Diabetes

Yes

5 (0–10)

6 (0–10)

5 (0–7)

95 (90–100)

94 (90–100) 95 (93–100)

Education level

Low

57 (50–75)

59 (52–70)

54 (44–68)

Middle

15 (5–22)

22 (12–31)

27 (15–36)

High

5 (0–10)

8 (0–14)

11 (0–17)

Missing

23 (0–33)

11 (0–13)

8 (0–6)

Marital status

Unmarried

10 (0–15)

9 (0–12)

9 (1–15)

Married

63 (55–77)

65 (57–75)

69 (61–78)

Divorced

4 (0–6)

7 (0–12)

9 (0–14)

Widower

22 (7–29)

18 (4–25)

13 (0–17)

Missing

0 (0–0)

Table 1 (

Continued

)

GnRH agonists as primary treatment in

experimental unit

0–33%

34–66%

67–100%

Primary treatment

GnRH agonists

19 (11–28)

53 (45–61)

87 (79–100)

Orchiectomy

81 (72–89)

47 (39–55)

13 (0–21)

GnRH = gonadotropin-releasing hormone.

Data are presented as total percentage/median with interquartile range

between experimental units (ie, combination of year, hospital and age

group) in parentheses.

World Health Organisation grade converted to Gleason score using the

rule G1 = GS 2–6, G2 = GS 7, and G3 = GS 8–10.

[(Fig._2)TD$FIG]

100

0.0

0.2

0.4

0.6

0.8

1.0

1.2

GnRH agonists by unit (%)

Relative risk of cardiovascular disease/death

Fig. 2 – Relative risk of cardiovascular disease (CVD) according to the

percentage of men who received gonadotropin-releasing hormone

(GnRH) agonists as primary

[7_TD$DIFF]

treatment in each experimental unit.

The

orange shading shows the 95% confidence interval. CVD was defined as first

occurrence of CVD (ICD-10 codes I00–I99). The total number of CVD events

was 5145, including 31% incident cases of other forms of heart disease (I30–

I52), 26% ischaemic heart disease (I20–I25), 15% cerebrovascular disease

(I60–I69), 11% hypertensive disease (I10–I15), 8% disease of the veins,

lymphatic vessels, and lymph nodes (I80–I89), 5% disease of the arteries,

arterioles, and capillaries (I70–I79), 3% pulmonary heart disease and disease

of the pulmonary circulation (I26–I28), and 1% others and unspecified (I00–

I09, I95–I99). Death from CVD was reported as the first occurrence of CVD

in 8% of the men

Table 2 – Relative risk of cardiovascular disease/death by

percentage exposure to GnRH agonists

RR (95% CI)

value

GnRH agonists

0–33%

1.00 (reference)

–

34–66%

1.04 (0.94–1.14)

0.5

67–100%

1.01 (0.93–1.11)

0.8

GnRH = gonadotropin-releasing hormone; RR = relative risk; CI = confidence

interval.

Risk estimated using ah Poisson model adjusted for T stage, M stage, Gleason

score, prostate-specific antigen, previous cardiovascular disease, previous

hypertension, and previous diabetes.

E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 2 0 – 9 2 8

923